Zusammenfassung Der Ständige Ausschuss Reisemedizin (StAR) der Deutschen Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit (DTG) gibt jährlich Empfehlungen zu Reiseimpfungen. Diese Empfehlungen werden von unabhängigen Experten erstellt. Sie umfassen international verpflichtende sowie länderspezifische und gefährdungsbasierte Impfstrategien. Sie dienen als Entscheidungshilfe für medizinisches Fachpersonal und berücksichtigen Empfehlungen u. a. der WHO, des ECDC, der STIKO und nationaler Gesundheitsbehörden.
Real-world treatments for 5q-spinal muscular atrophy (SMA) have evolved rapidly following the sequential approval of three disease-modifying treatments (DMTs): nusinersen, onasemnogene abeparvovec and risdiplam. The aim of this study was to map the sequence and timing of SMA treatments accurately using the SMArtCARE registry, a disease-specific registry for patients with SMA across 84 participating centres in Germany, Austria and Switzerland. All patients registered in SMArtCARE were included in the analysis. Patients were grouped based on their treatment regimen: those who remained on the first DMT versus those who switched DMT. The impacts of clinical and genetic factors on treatment decisions were evaluated, including age at initiation of treatment, SMN2 copy number, motor function status, the need for ventilator support or tube feeding, and the presence of scoliosis. A total of 2140 patients were included. Of these, 1294 patients (60.5%) initiated treatment with nusinersen, 514 patients (24.0%) with risdiplam and 243 patients (11.4%) with onasemnogene abeparvovec. Overall, 1366 patients (63.8%) remained on the first DMT. Most treatment switches occurred shortly after approval of a new DMT. Notably, most patients who switched showed no change in motor milestone status between the start of the first and the second DMT. In this large real-world cohort, we present the first comprehensive analysis of SMA treatment patterns across all age groups and disease severities. Although most patients remained on the first DMT, switches were observed, mainly after DMT approvals. Decisions to switch appear multifactorial and are not related directly to motor function effectiveness.
Segmentation based on psychographic criteria, such as values and lifestyles, is essential for effective market development and long-term growth, yet it remains costly, complex, and methodologically demanding in practice. This article introduces an AI-supported approach designed to overcome these challenges. We present the Value Map, an innovative framework that integrates large language models (LLMs) with established psychological value theories to enable scalable customer segmentation based on intrinsic values. The Value Map consists of nearly 500 distinct values that are organized in a structured, interpretable semantic space and can be used to guide and stabilize AI-based analyses of qualitative data. We demonstrate the applicability of this approach using large-scale textual data from thousands of active members of the Porsche Brand Community Rennlist, illustrating how the Value Map enables consistent and meaningful psychographic segmentation at scale. The method is further validated through expert focus groups involving marketing researchers and practitioners, who assess the usability, credibility, and practical relevance of the resulting segments. Overall, the findings advance theoretical understanding of psychographic and value-based segmentation and provide a transparent, AI-enabled tool that enhances the reliability and practical applicability of LLMs in market research and brand strategy.